Quick Answer
Cyclerion Therapeutics, Inc. reported Operating Income of -$4.97 million for fiscal year 2025.
Cyclerion Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$4.97M | -37.1% |
| 2024 | -$3.63M | +72.0% |
| 2023 | -$12.95M | +30.1% |
| 2022 | -$18.54M | +66.4% |
| 2021 | -$55.20M | +32.1% |
| 2020 | -$81.27M | +35.0% |
| 2019 | -$125.04M | -8.5% |
| 2018 | -$115.25M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.01M | +10.8% | +39.8% |
| June 30, 2025 | -$1.67M | -20.8% | -14.8% |
| March 31, 2025 | -$1.46M | +10.0% | -29.2% |
| September 30, 2024 | -$1.13M | +81.2% | +18.5% |
| June 30, 2024 | -$1.38M | +25.8% | +14.5% |
| March 31, 2024 | -$1.62M | +50.6% | +73.1% |
| September 30, 2023 | -$6.01M | -33.1% | -222.5% |
| June 30, 2023 | -$1.86M | +86.1% | +43.1% |
- Cyclerion Therapeutics, Inc. showed a decrease of -37.1% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Cyclerion Therapeutics, Inc.’s operating income has grown by 95.7% (from -$115.25 million to -$4.97 million).
- The most recent figure is from Cyclerion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: